ReviewCurrent opinion in pharmacology2009
Pathogen recognition receptors, cancer and inflammation in the gut.
Review in Current opinion in pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 82 citations in OpenAlex.
- Interplay between pathogen-mediated immune evasion and innate immune negative regulation in gastrointestinal tumors.Frontiers in immunology · 2026Review
- Designing and immuno-informatics evaluation of a multi-epitope vaccine targeting lipoprotein A-4'-phosphatase (LpxF) forFrontiers in bioinformatics · 2026Article
- The immunopathogenesis ofFrontiers in microbiology · 2024Review
- Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives.Biomarker research · 2022Review
- Gut microbiota: An emerging therapeutic approach of herbal medicine for prevention of colorectal cancer.Frontiers in cellular and infection microbiology · 2022Review
- Interferon b drives intestinal regeneration after radiation.Science advances · 2021Article
- Interactions of commensal and pathogenic microorganisms with the mucus layer in the colon.Gut microbes · 2020Review
- Microbiota: a novel regulator of pain.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.Clinical reviews in allergy & immunology · 2019Review
- Functional Polymorphisms and Gene Expression of TLR9 Gene as Protective Factors for Nasopharyngeal Carcinoma Severity and Progression.Journal of immunology research · 2019Article
- Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer.Nature reviews. Gastroenterology & hepatology · 2018Review
- AKT-targeted anti-inflammatory activity ofJournal of ginseng research · 2018Article
- Colorectal cancer prevention: Immune modulation taking the stage.Biochimica et biophysica acta. Reviews on cancer · 2018Review
- The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.Frontiers in immunology · 2018Review
- TLR Specific Immune Responses against Helminth Infections.Journal of parasitology research · 2017Review
- Coexpression Network Analysis of Benign and Malignant Phenotypes of SIV-Infected Sooty Mangabey and Rhesus Macaque.PloS one · 2016Article
- Effect of Helicobacter pylori eradication on TLR2 and TLR4 expression in patients with gastric lesions.Mediators of inflammation · 2015Article
- Interferon regulatory factor 6 differentially regulates Toll-like receptor 2-dependent chemokine gene expression in epithelial cells.The Journal of biological chemistry · 2014Article
- Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression.Journal of gastroenterology · 2014Article
- Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.OncoTargets and therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The pathogen recognition receptors (PRRs) initiate immediate responses against infection and tissue damage to protect the host from microbial invasion. In response to mucosal damage, intestinal PRR signaling initiates damage repair processes. Recent advances appear to link PRR abnormalities and inflammatory as well as neoplastic intestinal disorders. Emerging evidence suggests a dual role of PRRs, in which they may simultaneously induce tumorigenesis and antitumor immunity. PRR may induce tumor cell proliferation by activating cell survival signaling mainly via NF-kappaB, but this signal can activate dendritic cells to promote antitumor immunity. TLR signaling within the tumor cells may result in evasion of immune surveillance, propagation of metastatic growth, or rather, induction of tumor cell apoptosis depending on ligands. Epithelial cells induce endogenous PRR ligands when damaged or during neoplastic transformation. Targeted manipulation of PRR signaling may provide emerging opportunities for the development of new therapeutic strategies for many gastrointestinal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.